Active Pharmaceutical Ingredients Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By API ; By Manufacturer ; By Type of Drug ; By Therapeutic Area ; By Potency ; Region

Description

Global Active Pharmaceutical Ingredients (API) Market Size Booming to Touch USD 325 Billion by 2029.

Global active pharmaceutical ingredients (API) market is flourishing due to a high demand for cost-effective medicines driven by the increasing prevalence of chronic diseases across the world, expansion of generic drug manufacturing, and advancements in drug manufacturing technology.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global active pharmaceutical ingredients (API) market size was worth USD 232.4 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global active pharmaceutical ingredients (API) market size to grow at a CAGR of 5.69% reaching a value of USD 324.67 billion by 2029. The rising global burden of chronic diseases, such as cardiovascular diseases, cancer, and diabetes, is driving the demand for effective and cost-efficient treatment options. APIs form the backbone of pharmaceutical drugs, and the growing need for therapeutic interventions will lead to an increased demand for APIs to develop and manufacture these medications. Moreover, pharmaceutical companies are investing heavily in R&D activities to introduce innovative drugs and therapies. The increasing focus on R&D will further drive the demand for APIs as they are the key components in drug development. With advancements in technology and increasing investments in novel drug discoveries, the global active pharmaceutical ingredients (API) market is expected to witness substantial growth in the coming years.

Increasing demand for generic drugs:

Generic drugs are cost-effective alternatives to branded drugs, offering the same therapeutic benefits at lower prices. This affordability makes them accessible to a larger population, driving their demand and subsequently boosting the API market. As patents expire for branded drugs, generic drug manufacturers can enter the market with their versions, utilizing APIs to produce these cost-effective alternatives. This creates opportunities for API manufacturers to supply the necessary ingredients for generic drug production. For example, when the patent for a popular branded drug expires, multiple generic manufacturers can develop their versions using the same API. This leads to increased competition, resulting in lower prices and wider availability of the drug. As a result, patients and healthcare providers can choose more affordable options, reducing healthcare costs, and increasing accessibility. A study by the World Health Organization (WHO) found that generic drugs can save up to 80% of the cost of branded drugs. The WHO also estimates that generic drugs could save the global healthcare system USD 200 billion per year. As a result, governments and healthcare systems worldwide are actively promoting the use of generic drugs to reduce healthcare expenditures. In some cases, regulations may even mandate the prescription of generic drugs whenever possible. This policy support further drives the demand for generic drugs and, consequently, the growth of global API market. The growing demand for generic drugs is also fueled by the increasing prevalence of chronic diseases globally. As the population ages and chronic conditions become more prevalent, the need for cost-effective treatment options rises. Generic drugs, enabled by APIs, play a vital role in meeting the increasing demand and providing affordable healthcare solutions.

Segmental Information:

Global Active Pharmaceutical Ingredients (API) Market - By Therapeutic Area:

Based on therapeutic area, the global active pharmaceutical ingredients (API) market is segmented into the cardiovascular system, central nervous system, respiratory system, oncology, gastrointestinal system, and others. The cardiovascular system segment held the largest market share in the global active pharmaceutical ingredients (API) market, due to the prominence of cardiovascular drugs and therapies. Cardiovascular diseases, including heart diseases, stroke, and hypertension, are prevalent worldwide and remain one of the leading causes of morbidity and mortality. The increasing incidence of cardiovascular disorders, coupled with the aging population and lifestyle changes, drives the demand for pharmaceutical interventions in this therapeutic area. As a result, there is a substantial need for API-based medications targeting the cardiovascular system. The cardiovascular API market benefits from the continuous development of innovative treatments and therapies. Furthermore, cardiovascular drugs often require long-term treatment, contributing to a sustained demand for APIs in the cardiovascular therapeutic area. Patients with cardiovascular conditions typically require medications that help regulate blood pressure, manage cholesterol levels, and prevent blood clots. As these drugs are frequently prescribed and used over extended periods, the demand for cardiovascular APIs remains high. Governments and healthcare organizations worldwide also prioritize cardiovascular health due to its substantial economic and healthcare burden. Public health initiatives and awareness campaigns further drive the demand for cardiovascular medications, boosting the market growth for cardiovascular APIs.

Impact of COVID-19 on Global Active Pharmaceutical Ingredients Market:

The COVID-19 pandemic had a mixed impact on the global active pharmaceutical ingredients (API) market. While the demand for certain APIs surged due to the production of drugs and vaccines to combat the virus, other segments experienced disruptions. Supply chain disruptions, restrictions on trade, and raw material shortages impacted API manufacturing and distribution. The increased focus on healthcare preparedness and vaccine development during the pandemic drove the demand for APIs. The pandemic also highlighted the importance of domestic API production, leading to efforts by governments to strengthen local manufacturing capabilities. Overall, the COVID-19 pandemic reshaped the API market dynamics, emphasizing the need for resilient supply chains and domestic manufacturing capacities.

Competitive Landscape:

The global active pharmaceutical ingredients (API) market is fragmented, with many players serving the market. The key players dominating the global active pharmaceutical ingredients (API) market include Teva Pharmaceutical Industries Ltd, Pfizer Inc., Novartis International AG, Mylan N.V., Aurobindo Pharma Ltd, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Dr Reddy's Laboratories Ltd, Merck & Co., Inc., Lonza Group Ltd, Bristol-Myers Squibb, GlaxoSmithKline plc, AbbVie Inc., Lupin Limited, and Cipla Ltd. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisition to expand their customer reach and gain a competitive edge in the overall market.

The report's in-depth analysis provides information about growth potential, upcoming trends, and the Global Active Pharmaceutical Ingredients (API) Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Active Pharmaceutical Ingredients (API) Market along with industry insights to help decision-makers make sound strategic decisions. The report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Product Code: BWC19271

1. Research Framework

1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Executive Summary

3. Global Active Pharmaceutical Ingredients (API) Market Insights

3.1. Industry Value Chain Analysis
3.2. DROC Analysis
- 3.2.1. Growth Drivers
  - 3.2.1.1. Increasing demand for generic drugs
  - 3.2.1.2. Rising prevalence of chronic diseases
  - 3.2.1.3. Growing focus on research and development of new APIs
- 3.2.2. Restrains
  - 3.2.2.1. Stringent regulatory requirements
  - 3.2.2.2. Price volatility
- 3.2.3. Opportunities
  - 3.2.3.1. Growing demand from emerging markets
  - 3.2.3.2. Development of new technologies
- 3.2.4. Challenges
  - 3.2.4.1. Regulatory challenges
  - 3.2.4.2. Competition from generics
3.3. Technology Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry

4. Global Active Pharmaceutical Ingredients (API) Market Overview

4.1. Market Size & Forecast, 2019-2029
- 4.1.1. By Value (USD Million)
4.2. Market Share and Forecast
- 4.2.1. By API
  - 4.2.1.1. Synthetic API
  - 4.2.1.2. Biological API
- 4.2.2. By Manufacturer
  - 4.2.2.1. Captive Manufacturers
  - 4.2.2.2. Merchant Manufacturers
- 4.2.3. By Type of Drug
  - 4.2.3.1. Branded/Innovator Drugs
  - 4.2.3.2. Generic Drugs
- 4.2.4. By Therapeutic Area
  - 4.2.4.1. Cardiovascular System
  - 4.2.4.2. Central Nervous System (CNS)
  - 4.2.4.3. Respiratory System
  - 4.2.4.4. Oncology
  - 4.2.4.5. Gastrointestinal System
  - 4.2.4.6. Others
- 4.2.5. By Potency
  - 4.2.5.1. Traditional API
  - 4.2.5.2. HPAPI
- 4.2.6. By Region
  - 4.2.6.1. North America
  - 4.2.6.2. Europe
  - 4.2.6.3. Asia Pacific (APAC)
  - 4.2.6.4. Latin America (LATAM)
  - 4.2.6.5. Middle East and Africa (MEA)

5. North America Active Pharmaceutical Ingredients (API) Market

5.1. Market Size & Forecast, 2019-2029
- 5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
- 5.2.1. By API
- 5.2.2. By Manufacturer
- 5.2.3. By Type of Drug
- 5.2.4. By Therapeutic Area
- 5.2.5. By Potency
- 5.2.6. By Country
  - 5.2.6.1. United States
  - 5.2.6.1.1. By API
  - 5.2.6.1.2. By Manufacturer
  - 5.2.6.1.3. By Type of Drug
  - 5.2.6.1.4. By Therapeutic Area
  - 5.2.6.1.5. By Potency
  - 5.2.6.2. Canada
  - 5.2.6.2.1. By API
  - 5.2.6.2.2. By Manufacturer
  - 5.2.6.2.3. By Type of Drug
  - 5.2.6.2.4. By Therapeutic Area
  - 5.2.6.2.5. By Potency

6. Europe Active Pharmaceutical Ingredients (API) Market

6.1. Market Size & Forecast, 2019-2029
- 6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
- 6.2.1. By API
- 6.2.2. By Manufacturer
- 6.2.3. By Type of Drug
- 6.2.4. By Therapeutic Area
- 6.2.5. By Potency
- 6.2.6. By Country
  - 6.2.6.1. Germany
  - 6.2.6.1.1. By API
  - 6.2.6.1.2. By Manufacturer
  - 6.2.6.1.3. By Type of Drug
  - 6.2.6.1.4. By Therapeutic Area
  - 6.2.6.1.5. By Potency
  - 6.2.6.2. United Kingdom
  - 6.2.6.2.1. By API
  - 6.2.6.2.2. By Manufacturer
  - 6.2.6.2.3. By Type of Drug
  - 6.2.6.2.4. By Therapeutic Area
  - 6.2.6.2.5. By Potency
  - 6.2.6.3. Italy
  - 6.2.6.3.1. By API
  - 6.2.6.3.2. By Manufacturer
  - 6.2.6.3.3. By Type of Drug
  - 6.2.6.3.4. By Therapeutic Area
  - 6.2.6.3.5. By Potency
  - 6.2.6.4. France
  - 6.2.6.4.1. By API
  - 6.2.6.4.2. By Manufacturer
  - 6.2.6.4.3. By Type of Drug
  - 6.2.6.4.4. By Therapeutic Area
  - 6.2.6.4.5. By Potency
  - 6.2.6.5. Spain
  - 6.2.6.5.1. By API
  - 6.2.6.5.2. By Manufacturer
  - 6.2.6.5.3. By Type of Drug
  - 6.2.6.5.4. By Therapeutic Area
  - 6.2.6.5.5. By Potency
  - 6.2.6.6. Belgium
  - 6.2.6.6.1. By API
  - 6.2.6.6.2. By Manufacturer
  - 6.2.6.6.3. By Type of Drug
  - 6.2.6.6.4. By Therapeutic Area
  - 6.2.6.6.5. By Potency
  - 6.2.6.7. Russia
  - 6.2.6.7.1. By API
  - 6.2.6.7.2. By Manufacturer
  - 6.2.6.7.3. By Type of Drug
  - 6.2.6.7.4. By Therapeutic Area
  - 6.2.6.7.5. By Potency
  - 6.2.6.8. The Netherlands
  - 6.2.6.8.1. By API
  - 6.2.6.8.2. By Manufacturer
  - 6.2.6.8.3. By Type of Drug
  - 6.2.6.8.4. By Therapeutic Area
  - 6.2.6.8.5. By Potency
  - 6.2.6.9. Rest of Europe
  - 6.2.6.9.1. By API
  - 6.2.6.9.2. By Manufacturer
  - 6.2.6.9.3. By Type of Drug
  - 6.2.6.9.4. By Therapeutic Area
  - 6.2.6.9.5. By Potency

7. Asia-Pacific Active Pharmaceutical Ingredients (API) Market

7.1. Market Size & Forecast, 2019-2029
- 7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
- 7.2.1. By API
- 7.2.2. By Manufacturer
- 7.2.3. By Type of Drug
- 7.2.4. By Therapeutic Area
- 7.2.5. By Potency
- 7.2.6. By Country
  - 7.2.6.1. China
  - 7.2.6.1.1. By API
  - 7.2.6.1.2. By Manufacturer
  - 7.2.6.1.3. By Type of Drug
  - 7.2.6.1.4. By Therapeutic Area
  - 7.2.6.1.5. By Potency
  - 7.2.6.2. India
  - 7.2.6.2.1. By API
  - 7.2.6.2.2. By Manufacturer
  - 7.2.6.2.3. By Type of Drug
  - 7.2.6.2.4. By Therapeutic Area
  - 7.2.6.2.5. By Potency
  - 7.2.6.3. Japan
  - 7.2.6.3.1. By API
  - 7.2.6.3.2. By Manufacturer
  - 7.2.6.3.3. By Type of Drug
  - 7.2.6.3.4. By Therapeutic Area
  - 7.2.6.3.5. By Potency
  - 7.2.6.4. South Korea
  - 7.2.6.4.1. By API
  - 7.2.6.4.2. By Manufacturer
  - 7.2.6.4.3. By Type of Drug
  - 7.2.6.4.4. By Therapeutic Area
  - 7.2.6.4.5. By Potency
  - 7.2.6.5. Australia & New Zealand
  - 7.2.6.5.1. By API
  - 7.2.6.5.2. By Manufacturer
  - 7.2.6.5.3. By Type of Drug
  - 7.2.6.5.4. By Therapeutic Area
  - 7.2.6.5.5. By Potency
  - 7.2.6.6. Indonesia
  - 7.2.6.6.1. By API
  - 7.2.6.6.2. By Manufacturer
  - 7.2.6.6.3. By Type of Drug
  - 7.2.6.6.4. By Therapeutic Area
  - 7.2.6.6.5. By Potency
  - 7.2.6.7. Malaysia
  - 7.2.6.7.1. By API
  - 7.2.6.7.2. By Manufacturer
  - 7.2.6.7.3. By Type of Drug
  - 7.2.6.7.4. By Therapeutic Area
  - 7.2.6.7.5. By Potency
  - 7.2.6.8. Singapore
  - 7.2.6.8.1. By API
  - 7.2.6.8.2. By Manufacturer
  - 7.2.6.8.3. By Type of Drug
  - 7.2.6.8.4. By Therapeutic Area
  - 7.2.6.8.5. By Potency
  - 7.2.6.9. Vietnam
  - 7.2.6.9.1. By API
  - 7.2.6.9.2. By Manufacturer
  - 7.2.6.9.3. By Type of Drug
  - 7.2.6.9.4. By Therapeutic Area
  - 7.2.6.9.5. By Potency
  - 7.2.6.10. Rest of APAC
  - 7.2.6.10.1. By API
  - 7.2.6.10.2. By Manufacturer
  - 7.2.6.10.3. By Type of Drug
  - 7.2.6.10.4. By Therapeutic Area
  - 7.2.6.10.5. By Potency

8. Latin America Active Pharmaceutical Ingredients (API) Market

8.1. Market Size & Forecast, 2019-2029
- 8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
- 8.2.2. By Country
  - 8.2.2.1. Brazil
  - 8.2.2.1.1. By API
  - 8.2.2.1.2. By Manufacturer
  - 8.2.2.1.3. By Type of Drug
  - 8.2.2.1.4. By Therapeutic Area
  - 8.2.2.1.5. By Potency
  - 8.2.2.2. Mexico
  - 8.2.2.2.1. By API
  - 8.2.2.2.2. By Manufacturer
  - 8.2.2.2.3. By Type of Drug
  - 8.2.2.2.4. By Therapeutic Area
  - 8.2.2.2.5. By Potency
  - 8.2.2.3. Argentina
  - 8.2.2.3.1. By API
  - 8.2.2.3.2. By Manufacturer
  - 8.2.2.3.3. By Type of Drug
  - 8.2.2.3.4. By Therapeutic Area
  - 8.2.2.3.5. By Potency
  - 8.2.2.4. Peru
  - 8.2.2.4.1. By API
  - 8.2.2.4.2. By Manufacturer
  - 8.2.2.4.3. By Type of Drug
  - 8.2.2.4.4. By Therapeutic Area
  - 8.2.2.4.5. By Potency
  - 8.2.2.5. Rest of LATAM
  - 8.2.2.5.1. By API
  - 8.2.2.5.2. By Manufacturer
  - 8.2.2.5.3. By Type of Drug
  - 8.2.2.5.4. By Therapeutic Area
  - 8.2.2.5.5. By Potency

9. Middle East & Africa Active Pharmaceutical Ingredients (API) Market

9.1. Market Size & Forecast, 2019-2029
- 9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
- 9.2.1. By API
- 9.2.2. By Manufacturer
- 9.2.3. By Type of Drug
- 9.2.4. By Therapeutic Area
- 9.2.5. By Potency
- 9.2.6. By Country
  - 9.2.6.1. Saudi Arabia
  - 9.2.6.1.1. By API
  - 9.2.6.1.2. By Manufacturer
  - 9.2.6.1.3. By Type of Drug
  - 9.2.6.1.4. By Therapeutic Area
  - 9.2.6.1.5. By Potency
  - 9.2.6.2. UAE
  - 9.2.6.2.1. By API
  - 9.2.6.2.2. By Manufacturer
  - 9.2.6.2.3. By Type of Drug
  - 9.2.6.2.4. By Therapeutic Area
  - 9.2.6.2.5. By Potency
  - 9.2.6.3. Qatar
  - 9.2.6.3.1. By API
  - 9.2.6.3.2. By Manufacturer
  - 9.2.6.3.3. By Type of Drug
  - 9.2.6.3.4. By Therapeutic Area
  - 9.2.6.3.5. By Potency
  - 9.2.6.4. Kuwait
  - 9.2.6.4.1. By API
  - 9.2.6.4.2. By Manufacturer
  - 9.2.6.4.3. By Type of Drug
  - 9.2.6.4.4. By Therapeutic Area
  - 9.2.6.4.5. By Potency
  - 9.2.6.5. South Africa
  - 9.2.6.5.1. By API
  - 9.2.6.5.2. By Manufacturer
  - 9.2.6.5.3. By Type of Drug
  - 9.2.6.5.4. By Therapeutic Area
  - 9.2.6.5.5. By Potency
  - 9.2.6.6. Nigeria
  - 9.2.6.6.1. By API
  - 9.2.6.6.2. By Manufacturer
  - 9.2.6.6.3. By Type of Drug
  - 9.2.6.6.4. By Therapeutic Area
  - 9.2.6.6.5. By Potency
  - 9.2.6.7. Algeria
  - 9.2.6.7.1. By API
  - 9.2.6.7.2. By Manufacturer
  - 9.2.6.7.3. By Type of Drug
  - 9.2.6.7.4. By Therapeutic Area
  - 9.2.6.7.5. By Potency
  - 9.2.6.8. Rest of MEA
  - 9.2.6.8.1. By API
  - 9.2.6.8.2. By Manufacturer
  - 9.2.6.8.3. By Type of Drug
  - 9.2.6.8.4. By Therapeutic Area
  - 9.2.6.8.5. By Potency

10. Competitive Landscape

10.1. List of Key Players and Their Offerings
10.2. Global Active Pharmaceutical Ingredients (API) Market Share Analysis, 2022
10.3. Competitive Benchmarking, By Operating Parameters
10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Active Pharmaceutical Ingredients Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

12.1. Teva Pharmaceutical Industries Ltd
12.2. Pfizer Inc.
12.3. Novartis International AG
12.4. Mylan N.V.
12.5. Aurobindo Pharma Ltd
12.6. Sun Pharmaceutical Industries Ltd
12.7. Boehringer Ingelheim GmbH
12.8. Dr. Reddy's Laboratories Ltd
12.9. Merck & Co., Inc.
12.10. Lonza Group Ltd
12.11. Bristol-Myers Squibb
12.12. GlaxoSmithKline plc
12.13. AbbVie Inc.
12.14. Lupin Limited
12.15. Cipla Ltd
12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

14.1. Qualitative Research
- 14.1.1. Primary & Secondary Research
14.2. Quantitative Research
14.3. Market Breakdown & Data Triangulation
- 14.3.1. Secondary Research
- 14.3.2. Primary Research
14.4. Breakdown of Primary Research Respondents, By Region
14.5. Assumptions & Limitations